贝达药业：盐酸恩沙替尼胶囊上市许可申请获欧洲药品管理局受理

Core Viewpoint - Xcovery, a subsidiary of BeiGene, has received acceptance from the European Medicines Agency (EMA) for its marketing authorization application for ensartinib capsules, intended for the treatment of adult patients with ALK-positive locally advanced or metastatic non-small cell lung cancer (NSCLC) [1] Group 1 - Xcovery is a controlling subsidiary of BeiGene [1] - The application submitted by Xcovery is specifically for ensartinib capsules [1] - The target patient population for this treatment includes adults with ALK-positive locally advanced or metastatic NSCLC [1]